RENO, Nev., June 28, 2012 /PRNewswire/ -- Lifeline
Biotechnologies, Inc. (PINKSHEETS: LLBO) announces the USPTO has
awarded US Patent #8,185,485 B2 for a Device for Analyzing Thermal
Data Based on Breast Surface Temperature for the Detection for use
in Determining Cancerous Conditions.
"This has taken considerable effort to reach the conclusion of a
milestone that started with our clinical trials and a patent filing
August 27, 2008. We knew our
core science charted new territory and was unique because it took
considerable resources to achieve our results," says Jim Holmes, Chairman/CEO.
"The foundation of this Company is our two issued patents
(developed data collection device and the software patent above
referenced) together with two pending patents (a software patent
and a methods patent). Based on this intellectual property,
we are supporting our licensee, First Warning Systems, Inc. in
moving ahead with investment and commercialization plans," adds
Holmes.
About Lifeline Biotechnologies
Lifeline Biotechnologies, Inc. (OTC Market: LLBO) founded in 1994
is based in Reno, NV. LLBO
has invested over $10M in a device
and process for early detection of breast tissue abnormalities some
of which are cancerous or pre-cancers. Two patents are
awarded, two patents are pending; three clinical trials with over
650 participants have been completed. Proof of Concept has
been confirmed. www.lbti.com
Safe Harbor: This release includes forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933 and
Section 27E of the Securities Act of 1934. Statements contained in
this release that are not historical facts may be deemed to be
forward-looking statements. Investors are cautioned that
forward-looking statements are inherently uncertain. Actual
performance and results may differ materially from that projected
or suggested herein due to certain risks and uncertainties
including, without limitation, the ability to obtain financing,
successful development of the Company's product or market
acceptance of the product and regulatory and shareholder approval
for anticipated actions.
For more information, contact:
Jim Holmes, CEO
P: 775-324-1933 E: jholmes@lbti.com
SOURCE Lifeline Biotechnologies, Inc.